Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 526 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard CT Imaging Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Positron Emission Tomography/Computed Tomography (PECT/CT) Double-Scanning Study

NCT07857161
View directory record Official record
Conditions
PET/CT
Interventions
Omni 128cm PET/CT
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 4:49 AM EDT
Recruiting Phase 4 Interventional

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

NCT05919329
View directory record Official record
Conditions
Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer, Prostate Adenocarcinoma
Interventions
Piflufolastat, PSMA PET/CT Scan, PSMA PET/MRI scan, Biospecimen Collection, Electronic Health Record Review
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 4:49 AM EDT
Recruiting Phase 2 Interventional

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

NCT05554302
View directory record Official record
Conditions
Brain Metastases, Brain Cancer
Interventions
18F-Fluciclovine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 23, 2026, 4:49 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

PSMA PET and MRI in Gynecological Cancers

NCT03302156
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
PSMA-based 18F-DCFPyL PET tracer
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 23, 2026, 4:49 AM EDT
Recruiting Phase 1 Interventional

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

NCT05422794
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nab-paclitaxel, Pembrolizumab
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • Mineola, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 4:49 AM EDT
Recruiting Phase 1 Interventional

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT06622005
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Cxcr1/2 Inhibitor SX-682, Daratumumab and Recombinant Human Hyaluronidase, Carfilzomib, Dexamethasone, Biospecimen Collection, Bone Marrow Aspiration, Echocardiography, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 4:49 AM EDT
Completed No phase listed Observational

Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy

NCT01516866
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
3
States / cities
Bethesda, Maryland • New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 23, 2026, 4:49 AM EDT
Active, not recruiting Phase 1 Interventional

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

NCT03465618
View directory record Official record
Conditions
Brain Cancer, Pituitary Adenoma
Interventions
89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging, Blood and Urine samples
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 23, 2026, 4:49 AM EDT
Terminated Not applicable Interventional Results available

Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab

NCT03412630
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Computed Tomography Perfusion Imaging
Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 23, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

Targeted Fusion Biopsy of the Prostate

NCT02744534
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
FACBC PET-CT Scan, Three-dimensional ultrasound-guided biopsy, Standard transrectal ultrasound (TRUS) guided biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 23, 2026, 4:49 AM EDT
Recruiting Not applicable Interventional

Low-Count Quantitative SPECT for Men Treated With Radium-223

NCT07221825
View directory record Official record
Conditions
Prostate Cancer, Cancer of the Prostate
Interventions
Low-count quantitative single-photon emission computed tomography imaging
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 4:49 AM EDT
Completed Phase 1 Interventional

Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer

NCT00858663
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
intensity modulated radiation therapy, RAD001 (everolimus) + Cisplatin
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 23, 2026, 4:49 AM EDT
Recruiting Phase 2 Interventional

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

NCT07393867
View directory record Official record
Conditions
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
Interventions
PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
Diagnostic Test · Drug · Radiation
Lead sponsor
Martin T. King, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 4:49 AM EDT
Not yet recruiting Phase 2 Interventional

Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial

NCT07783581
View directory record Official record
Conditions
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Photon Stereotactic Body Radiation Therapy, Positron Emission Tomography, Spatially-fractionated Radiation Therapy, Surgical Procedure
Procedure · Biological · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 4:49 AM EDT
Recruiting Phase 2 Interventional

A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

NCT05544136
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma
Interventions
18F-FMISO PET/CT scan, Chemoradiation therapy, Carboplatin
Diagnostic Test · Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 4:49 AM EDT
Completed Early Phase 1 Interventional Results available

The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma

NCT01673802
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
CT scan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 23, 2026, 4:49 AM EDT
Not yet recruiting Phase 2 Interventional

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

NCT07517705
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy
Radiation · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 23, 2026, 4:49 AM EDT
Terminated Not applicable Interventional

PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer

NCT02042053
View directory record Official record
Conditions
Prostate Cancer
Interventions
PET/CT, PET/MRI
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 23, 2026, 4:49 AM EDT
Recruiting Phase 3 Interventional

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

NCT07578116
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, Echocardiography Test, HER2-targeted Therapy, Hormone Therapy, Magnetic Resonance Imaging, Mammography, Pertuzumab, Positron Emission Tomography, Radiation Boost, Radiation Therapy, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Taxane Compound, Total Mastectomy, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Ultrasound Imaging
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2033
U.S. locations
59
States / cities
Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 4:49 AM EDT
Completed No phase listed Observational Results available

Advanced Visuohaptic Surgical Planning for Trauma Surgery

NCT01056302
View directory record Official record
Conditions
Maxillofacial Injuries
Interventions
Surgical repair of mandibular fractures
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 23, 2026, 4:49 AM EDT
Active, not recruiting Phase 1 Interventional

Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

NCT04609592
View directory record Official record
Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Interventions
Lutathera, Gallium 68 Dotatate, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), PET/CT
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 4:49 AM EDT
Recruiting Phase 1 Interventional

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer

NCT05945875
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Panitumumab-IRDye800, Indium In 111 Panitumumab, Single Photon Emission Computed Tomography, Computed Tomography, Resection, Fluorescence Imaging
Drug · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 23, 2026, 4:49 AM EDT
Withdrawn Phase 2 Interventional

A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors

NCT04791228
View directory record Official record
Conditions
Solid Tumors, Soft Tissue Sarcoma, Ewing Sarcoma, Malignant Epithelial Neoplasm, Rhabdomyosarcoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Bone Metastases
Interventions
Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin
Device · Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 23, 2026, 4:49 AM EDT